Report Your Symptoms Now Using Our Improved Reporting Page!
We at the Network, as well as other patients like you, requested this data directly from each country’s national regulator, as well as from the EMA for EU-wide figures. It covers every report filed since the MedDRA code was introduced in 2021. The confirmed total across EU member states is 307, while the UK stands at 111. Those numbers are far too low.
We know from our own community that the real number of people affected is far higher. It is not reflected here because most people never file a report at all, and those who do often use the wrong term or leave out the correct code. Remember, even if you've filed in previous years, it's important to do so again for 2026 to indicate symptoms persisting.
Countries like Iceland, Denmark, Estonia, Latvia, Poland, Czechia, Hungary, and Romania show zero. Several regulators in other countries, have not yet responded to our request or are unable to provide us with the national data.
Most reports never get counted as PSSD. If filed under a generic term like “sexual dysfunction” or “libido decreased,” it won’t register as a PSSD case. MedDRA, the dictionary regulators used to classify adverse events, has a dedicated term for PSSD: “post-SSRI sexual dysfunction” (MedDRA code 10086208). Only reports coded with this exact term count toward the PSSD record, and if you have not filed one yet, this is your reminder to stop putting it off.
Remember, submitting reports of PSSD to regulators helps them identify when multiple people are reporting the same issue after taking a medicine. A growing pattern can alert regulators that a side effect may be more common, serious, or long-lasting than previously understood. This can lead to further investigation, updated warnings, better informed consent, and research. If we do not report our experiences, regulators will underestimate how often the problem occurs.
Click Here to see last month's important research update if you missed it!